Authors
Mengna Chi, Ammar Husami, Fabienne Lucas, Tahereh Setayesh, Zhenqi Zhu, Harsimran Kaur, Shristi Khanal, Anifat Tijani, Jing Chen, Wenying Zhang, Punam Malik
Published in
Blood. Nov 16, 2026. Epub Nov 16, 2026.
Abstract
Sickle cell disease (SCD) affects millions globally, causing significant lifelong morbidity and early death. As childhood mortality is reduced and SCD patients are surviving to adulthood, increased risk of hematological malignancy (HM) is becoming evident. Risk of therapy-related myelodysplastic syndrome (MDS)/acute myeloid leukemia, following gene therapy or hematopoietic stem cell transplant (HSCT) is also higher in SCD. The specific pathobiology that predisposes to HM is necessary to address, since survival has improved and gene therapy and HSCT are being increasingly used. We modelled the increased risk of HM in humanized SCD mice, compared to age-, sex- and strain-matched normal counterparts. We serially monitored hematopoiesis in blood and bone marrow up to 1-year-of-age and performed highly sensitive, error-corrected deep sequencing of 450 MDS/HM-associated genes. Unlike controls, SCD mice showed an 'ageing-like' phenotype with premature development of myeloid-biased hematopoiesis and hematopoietic stem/progenitor cells (HSPC) mutational profile characteristic of aged mice/humans. Furthermore, a high proportion of SCD mice developed hematopoiesis with dysplastic features reminiscent of MDS morphology and higher clonal hematopoiesis burden. Imposition of regenerative stress by serial HSCT further increased HSPC mutational burden, resulting in evolution/expansion of clones harboring oncogenic driver mutations. Our study indicates that increased HSC regenerative stress, imposed either by chronic erythropoietic demand or via autologous HSCT in SCD increases the risk of developing clonal hematopoiesis and MDS-like features. Our study provides insights into a mechanism underlying increased risk of HM in this non-malignant hematological disorder, and suggests that early intervention with curative therapies may circumvent this risk.
PMID:
43038169
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 27
- Comments 0